Cerebral Small Vessel Diseases Clinical Trial
— MOCSSOfficial title:
A Multicenter Prospective Cohort Study of Multimodal MRI in Cerebral Small Vessel Disease and Covert Stroke in Perioperative Patients
NCT number | NCT04443933 |
Other study ID # | KY2019-147 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 1, 2020 |
Est. completion date | December 2023 |
MOCSS study is a multicenter prospective clinical cohort study. The purpose of the MOCSS study is to investigate whether there is a correlation between the preoperative cerebral small vessel disease and the incidence of covert stroke after non-cardiac surgery. Cerebral small vessel disease (CSVD) and covert stroke will be diagnosed using multimodal MRI. This study will also investigate whether preoperative CSVD and postoperative covert stroke are related to postoperative cognitive dysfunction and delirium.
Status | Recruiting |
Enrollment | 548 |
Est. completion date | December 2023 |
Est. primary completion date | August 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years to 85 Years |
Eligibility | Inclusion Criteria: - Age from 65 years to 85 years; - The patient is about to have major surgery for the first time and the operation is non-cardiac surgery; - Written informed consent is obtained before the surgery. Exclusion Criteria: - mental illness; - Already have other diseases that can cause dementia, such as Alzheimer's disease, Lewy body dementia, Frontotemporal dementia, progressive supranuclear palsy, Parkinson's disease, Creutzfeldt-Jakob disease, Huntington's disease, alcohol and drug dependence, Neurosyphilis, systemic lupus erythematosus; or preoperative MRI shows hippocampal and temporal lobe atrophy more than two levels, suggesting the possibility of Alzheimer's disease - Have suffered from other brain diseases (such as stroke, multiple sclerosis, central nervous system infection with sequelae, etc.); - Preoperative MRI indicates covert stroke - MMSE or MoCA scale cannot be completed due to other reasons (such as hearing impairment or visual impairment) - MRI contraindications before or after surgery or patients who cannot tolerate MRI imaging - Stage 3 or 4 malignant tumors, and high malignancy and poor prognosis cancer, such as pancreatic cancer, gallbladder cancer, and bile duct cancer. |
Country | Name | City | State |
---|---|---|---|
China | Renji Hospital, Shanghai Jiaotong University School of Medicine | Shanghai |
Lead Sponsor | Collaborator |
---|---|
RenJi Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of postoperative covert stroke | We will use MRI to detect postoperative covert stroke as soon as patients can tolerate MRI. | 14 days | |
Secondary | Incidence of overt stroke after surgery | Incidence of overt stroke will be measured by obtaining medical history. | 3 months, 6 months and 12 months | |
Secondary | Modified Rankin Scale after surgery | The Modified Rankin Scale measures the degree of disability or dependence in the daily activities of people after stroke or other neurological disability.Minimum value:0, Maximum value:6. Higher scores mean a worse outcome. | 3 months, 6 months and 12 months | |
Secondary | Cognitive Function assessed by Montreal Cognitive Assessment Scale | We will use Montreal Cognitive Assessment (MoCA) scale to assess cognitive function after surgery. Minimum value:0, Maximum value: 30. Higher scores mean a better outcome. | 3 months, 6 months and 12 months | |
Secondary | Cognitive Function assessed by Mini-Mental State Examination Scale | We will use Mini-Mental State Examination (MMSE) scale to assess cognitive function after surgery. Minimum value:0, Maximum value: 30. Higher scores mean a better outcome. | 3 months, 6 months and 12 months | |
Secondary | Incidence of delirium | Incidence of delirium will be measured using Intensive Care Unit-Cognitive Assessment Method (ICU-CAM) every 12 hours till the 72 hours after surgery. | 72 hours | |
Secondary | Physical functions after surgery | The investigators will use Activities of daily living (ADL) scale to measure physical function after surgery. Minimum value:0, Maximum value: 78. Higher scores mean a better outcome. | 3 months, 6 months and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04041349 -
Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease
|
Phase 4 | |
Recruiting |
NCT04109963 -
Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment
|
Phase 2 | |
Not yet recruiting |
NCT06416371 -
Retinal Vessel Leakage in Cerebral Small Vessel Disease
|
||
Not yet recruiting |
NCT05967728 -
Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care
|
Phase 2 | |
Completed |
NCT05714813 -
Circuit Training and Retina
|
N/A | |
Not yet recruiting |
NCT06077305 -
A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
|
||
Not yet recruiting |
NCT06061692 -
Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD)
|
Phase 4 | |
Recruiting |
NCT04962295 -
China Imaging-based Biobank of Cerebral Small Vessal Diseases
|
||
Completed |
NCT02801032 -
Effect of Tadalafil on Cerebral Large Arteries in Stroke
|
Phase 2 | |
Not yet recruiting |
NCT05594966 -
Neuroimaging Combining Biomarkers for Identifying Long-term Cognitive Dysfunction and Delirium
|
||
Terminated |
NCT02890888 -
Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease
|
N/A | |
Recruiting |
NCT04318119 -
Cerebral Small Vessel Disease Registry Study
|
||
Recruiting |
NCT03906123 -
The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia
|
N/A | |
Recruiting |
NCT05306834 -
Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease
|
N/A | |
Not yet recruiting |
NCT05583266 -
Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)
|
Phase 4 | |
Recruiting |
NCT05173896 -
Improving Cerebral Blood Flow and Cognition in Patients With Cerebral Small Vessel Disease. The ETLAS-2 Trial
|
Phase 2 | |
Recruiting |
NCT01819441 -
Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients
|
Phase 4 | |
Recruiting |
NCT01688505 -
Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function
|
N/A | |
Recruiting |
NCT04330222 -
Cambridge 7 Tesla Cerebral Small Vessel Disease Study
|
||
Recruiting |
NCT04298866 -
White Matter Hyperintensities Subtypes in Cerebral Small Vessel Disease : 7 Tesla Ultra-high Resolution Imaging MRI
|
N/A |